Clinical validity of increased cortical uptake of amyloid ligands on PET as a biomarker for Alzheimer's disease in the context of a structured 5-phase development framework.
about
Clinical validity of increased cortical uptake of amyloid ligands on PET as a biomarker for Alzheimer's disease in the context of a structured 5-phase development framework.
description
2017 nî lūn-bûn
@nan
2017 թուականի Ապրիլին հրատարակուած գիտական յօդուած
@hyw
2017 թվականի ապրիլին հրատարակված գիտական հոդված
@hy
2017年の論文
@ja
2017年論文
@yue
2017年論文
@zh-hant
2017年論文
@zh-hk
2017年論文
@zh-mo
2017年論文
@zh-tw
2017年论文
@wuu
name
Clinical validity of increased ...... 5-phase development framework.
@ast
Clinical validity of increased ...... 5-phase development framework.
@en
type
label
Clinical validity of increased ...... 5-phase development framework.
@ast
Clinical validity of increased ...... 5-phase development framework.
@en
prefLabel
Clinical validity of increased ...... 5-phase development framework.
@ast
Clinical validity of increased ...... 5-phase development framework.
@en
P2093
P50
P1476
Clinical validity of increased ...... 5-phase development framework.
@en
P2093
Agnese Picco
Andrea Varrone
Geneva Task Force for the Roadmap of Alzheimer's Biomarkers
Karl Herholz
Laure Saint-Aubert
Marina Boccardi
P304
P356
10.1016/J.NEUROBIOLAGING.2016.07.012
P577
2017-04-01T00:00:00Z